Adamas Pharma (ADMS) Announces ADS-5102 Phase 3 Met Primary, Key Secondary Endpoints as LID Treatment


(April 29, 2016) - Adamas Pharmaceuticals, Inc.announced that its Phase 3 trial evaluating ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease met its primary and key secondary endpoints. Read more…

Click for a printer friendly version

Back to top